VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Consensus Rating of “Reduce” by Analysts

by · The Cerbat Gem

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN – Get Free Report) have earned an average recommendation of “Reduce” from the five brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $0.95.

A number of equities research analysts have recently issued reports on VTGN shares. William Blair lowered VistaGen Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Maxim Group cut VistaGen Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Stifel Nicolaus lowered shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a research note on Wednesday. Jefferies Financial Group downgraded shares of VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $0.90 target price on the stock. in a research report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, October 8th.

Check Out Our Latest Research Report on VistaGen Therapeutics

VistaGen Therapeutics Trading Down 80.2%

VTGN stock traded down $3.50 on Wednesday, hitting $0.86. 67,064,685 shares of the company’s stock traded hands, compared to its average volume of 657,980. The stock has a market cap of $34.04 million, a price-to-earnings ratio of -0.47 and a beta of 0.56. VistaGen Therapeutics has a 1-year low of $0.75 and a 1-year high of $5.14. The stock has a fifty day moving average of $4.20 and a 200-day moving average of $3.32.

VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.03). The business had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.16 million. On average, equities research analysts anticipate that VistaGen Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Trading of VistaGen Therapeutics

Hedge funds have recently modified their holdings of the business. AdvisorShares Investments LLC raised its holdings in shares of VistaGen Therapeutics by 1.9% during the 3rd quarter. AdvisorShares Investments LLC now owns 206,998 shares of the company’s stock valued at $735,000 after purchasing an additional 3,884 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in VistaGen Therapeutics during the first quarter worth $25,000. Schonfeld Strategic Advisors LLC bought a new position in VistaGen Therapeutics during the third quarter valued at about $39,000. Boothbay Fund Management LLC lifted its position in shares of VistaGen Therapeutics by 10.8% in the third quarter. Boothbay Fund Management LLC now owns 197,024 shares of the company’s stock worth $699,000 after buying an additional 19,166 shares during the last quarter. Finally, Bank of America Corp DE boosted its stake in shares of VistaGen Therapeutics by 1,068.0% during the 4th quarter. Bank of America Corp DE now owns 21,141 shares of the company’s stock worth $62,000 after acquiring an additional 19,331 shares in the last quarter. Hedge funds and other institutional investors own 78.39% of the company’s stock.

About VistaGen Therapeutics

(Get Free Report)

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.

Featured Articles